Davis Polk acted as special product counsel to the representatives of the initial purchasers in connection with a Rule 144A offering by Novavax, Inc. of an aggregate principal amount of $300 million of its 3.75% convertible senior notes due 2023. In addition, Davis Polk advised the counterparties to capped call transactions in connection with the offering.

Headquartered in Gaithersburg, Maryland, Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

The Davis Polk equity derivatives team included partner Ray Ibrahim and associates Mark J. DiFiore, Robert Stewart, Caitlin L. Wood and Mo Zhou. The tax team included partner Lucy W. Farr and associate Anne E. McGinnis. All members of the Davis Polk team are based in the New York office.

Copy link to share post